Trends in Mid-sized European Licensing
Executive Summary
Mid-sized European drug firms have traditionally spent considerably more on in-licensing than they've received from licensing out their products to other partners. But over the past two years, we've detected a dramatic shift in the ratio of dollars spent versus received in alliances.